Katherine Nathanson, M.D.


Payal Shah, M.D.


Tracy Stockley, Ph.D.

This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, and a post-test. Continuing education credit is available for the webinar.

Description: In this webinar, Drs. Nathanson and Shah will describe the biological basis for pathogenicity of variants and the clinical interpretation of genetic testing results. Additionally the speakers will provide insight into the clinical significance of pathogenic variants with a focus on BRCA1 and BRCA2, including risk mitigation measures and therapeutic implications.

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: October 29, 2021

CE Information:


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CMLE: This activity has been planned and implemented in accordance with the Amedco and joint provider-ship of the American Society for Clinical Pathology (ASCP) and the Association for Molecular Pathology (AMP). ASCP CMLE credit hours are acceptable for the ASCP Board of Certification Maintenance Program (CMP)

American Board of Pathology Self-Assessment Credit: This course is valid for up to 1.0 of SA-CME Self-Assessment credits (SAMs). Learners should self-submit these credits to their boards.

“Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors” is an up-to-date and useful three-part webcast series that will cover: 1. The mechanism of action of PARP inhibitors and the science of Homologous Recombination Deficiency (HRD) testing, 2. Laboratory considerations (from sample acquisition to result reporting) for HRD testing, and 3. Clinical considerations for testing and treatment and the need for genetic counseling.

This program has been supported through educational grants from AstraZeneca & Merck

You may also be interested in:

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
October 29, 2019
Course Objectives
  • Discuss the interpretation of variants in BRCA1/2, touching on genotype/phenotype correlation
  • Describe the three major categories of genetic testing results (benign, variant of uncertain significance, pathogenic/likely pathogenic)
  • Explain the main cancer prevention measures suggested for individuals with germline BRCA1 and BRCA2 mutations
  • Describe the current role of PARP inhibitors in the clinic
PARP Inhibitors in the Clinic: The Implications of Genetic Testing for Treatment Selection and Germline Counseling
Followup and Claiming CE Credit
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
American Medical Association
Continuing Medical Education: 1.00
American Society for Clinical Pathology
CMLE: 1.00
Nathanson & Shah Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00